Nona Biosciences

🌟 Excited to Announce: Nona Biosciences as the Premier Partner at IO Summit US in Philadelphia, August 7-9! Join us at Booth #11 and don't miss our plenary luncheon on August 8th at 12:15 PM with Dr. Joe Zhao, Head of External Innovation Nona Biosciences discussing the versatility of HCAb Harbour Mice® for next-gen therapeutics. 📊 Explore our posters: #P20: Fully Human Heavy Chain Only Antibodies to BCMA Identified by NonaCarFx™ Platform. #P21: Discovery of T Cell Receptor Mimic Antibody. We look forward to connecting with you there! For inquiries, reach out to us at [email protected]. #Antibody #AntibodyTherapeutics #AntibodyEngineering #AntibodyDiscovery #FullyHuman #HeavyChainOnlyAntibody #SingleDomainAntibody #HCAb #HarbourMice #mRNA #CAR_T #ADC #Bispecific #Multispecific #CancerTherapy #ImmunoOncology #Oncology #Immunology #IOSummit

🌟 Excited to attend the mRNA-Based Therapeutics Summit on July 30-31 in Boston, MA! Join Nona Biosciences as we unveil our groundbreaking advancements in LNP technology, poised to revolutionize biotherapeutics with unparalleled precision and efficacy! 🔬 Nanoparticle Targeted Delivery: 🔸Tissue and cell-specific targeting strategies. 🔹Innovative antibody-LNP conjugation enhancing endocytosis. 🚀 Cutting-Edge Platforms: 🔸mRNA-LNP encoding for targeted genetic delivery. 🔹Antibody-conjugated nanoparticles for precise therapeutic targeting. 🔸HCAb CARFx accelerating CAR-T therapy and in vivo CAR-T technology. Let’s pioneer the future of biotherapeutics together! For collaboration opportunities, contact us at [email protected]. #Biotechnology #LNP #TargetedTherapies #Innovation #Biotherapeutics #NonaBiosciences

🌟 Revolutionizing Medical Science: The Story of the Harbour HCAb Mice Platform Discover the incredible journey behind the creation of the Harbour HCAb mice platform by Dr. Frank Grosveld and his pioneering research team. This groundbreaking innovation is set to transform the landscape of medical science, pushing the boundaries of what's possible in research and healthcare. 👉 Take a look at what our HCAb Harbour Mice® is capable of https://lnkd.in/eF2VTc3j #HCAb #heavychainonly #antibodies #Innovation #Research #Breakthrough #HCAbMice #Harbour

🚀 Exciting Collaboration Announcement 🚀   We are excited to announce that Nona Biosciences has entered into a collaboration agreement with Alaya.bio to advance CAR-T cell therapy!   This partnership leverages Nona’s proprietary HCAb Harbour Mice® platform and its newly introduced site-specific conjugation technology, alongside Alaya.bio’s polymeric in situ delivery platform, aiming to develop CAR-T product candidates for potential clinical applications.   Unlike traditional methods that utilize non-specific conjugation technology, Nona’s novel site-specific conjugation technology preserves the antibody’s binding and function, thereby enhancing the specificity of Alaya.bio’s novel polymeric delivery systems while reinforcing the versatility of the platform. With Nona’s technology, Alaya.bio has identified promising new-generation candidates that clearly differentiate from what exists and from what has been used by others.   Stay tuned for further updates as we embark on this significant journey! Learn more: https://lnkd.in/g-hKcPQR #NonaBiosciences #Biotech #Innovation #CARTherapy #Antibody #HCAb

The HCAb Harbour Mice® platform, the world's first to produce fully human heavy chain antibodies (HCAb), pioneers a new generation of antibodies. These HCAbs are half the size of traditional IgG antibodies, with similar metabolic and effector functions, eliminating the need for extra humanization. The human germline gene's composition has been optimized to achieve the best developability. Their unique structure, lacking light chains, reduces issues like light chain mismatch. These advantages make HCAb a superior tool in antibody research and development. To learn more about Nona Biosciences' fully human HCAb Harbour Mice® platform, visit us at https://nonabio.com/ and contact us at [email protected] #AntibodyTherapy #HCAb #HarbourMice #NonaBiosciences #NextGenTherapies #SingleDomainAntibody #HeavyChainOnlyAntibody #Immunotherapy #InnovativeMedicine

👏 Nona Employee Spotlight: let's meet Ms. Changjing Deng 👏 Ms. Changjing Deng: "I transferred to Nona when Nona Suzhou site started. Together with a team full of passionate and talented individuals, I became one of the pioneers who practically applied this industrial leading single-cell screening platform to antibody discovery. Throughout the challenging process, we finally optimized the integration of SBC platform with Harbour Mice®. Over 80% of the company's antibody discovery projects are coming from the SBC platform now. This includes the candidate antibodies for the two recent successful campaigns that the company collaborated on with Pfizer and AstraZeneca. Growing together with the company, the five years' experience has become an indispensable part of my life."

Innovative Solutions by Nona Biosciences — Leading the way with high-affinity, specific TCR mimic (TCRm) antibodies designed to revolutionize cancer immunotherapy. Click further to find out why they are a game-changer. For more information, visit our website to learn more: https://lnkd.in/eT-_VkKp #CancerResearch #Immunotherapy #TCRmAntibodies #NonaBiosciences #MedicalInnovation #HealthTech #BiotechRevolution

👏 Nona Employee Spotlight: let's meet Dr. Jason Noon 👏 Dr. Jason Noon: "I chose to work here to leverage my expertise in immunology and molecular biology to discover and develop innovative therapeutics for patients with high unmet medical needs. With the unique Harbour Mice® technologies and extraordinary experience of the antibody discovery and development teams across the globe, my time here has far exceeded my expectations.   I am thrilled to work here because the efforts from myself and my team have been highly valued. My job entails leading the antibody discovery efforts at Nona US for cell therapy and other applications. The happiest moment at Nona was when our US Research Team was recognized and rewarded for developing a highly innovative and novel antibody screening platform called NonaCarFx™, which has gained tremendous traction both internally and externally."

🔬 Unlocking New Horizons in Cancer Therapy with TCRm Antibodies NOW! TCR mimic (TCRm) antibodies are revolutionizing the field of immunotherapy, offering unique advantages over traditional antibody and TCR-based therapies. Here’s why they stand out: - 𝗜𝗻𝘁𝗿𝗮𝗰𝗲𝗹𝗹𝘂𝗹𝗮𝗿 𝗔𝗻𝘁𝗶𝗴𝗲𝗻 𝗧𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 - 𝗛𝗶𝗴𝗵 𝗔𝗳𝗳𝗶𝗻𝗶𝘁𝘆 - 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗣𝗿𝗼𝗽𝗲𝗿𝘁𝗶𝗲𝘀 - 𝗠𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺𝘀 𝗼𝗳 𝗔𝗰𝘁𝗶𝗼𝗻 - 𝗘𝗮𝘀𝗲 𝗼𝗳 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 Check out this page to learn more: https://lnkd.in/eT-_VkKp #CancerImmunotherapy #TCRmAntibody #newproductlaunch #MedicalBreakthrough #HBICE #BITE

2-day countdown to a breakthrough in cancer treatment! Introducing the TCR mimic (TCRm) antibody – a revolutionary approach to targeting cancer cells with precision. Designed to harness the power of the immune system, TCRm is set to change the landscape of cancer treatment. Stay tuned for the unveiling of a game-changing innovation in immunotherapy. #CancerImmunotherapy #TCRmAntibody #3DaysToGo #MedicalBreakthrough #StayTuned